Compare LCII & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | TRVI |
|---|---|---|
| Founded | 1956 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | LCII | TRVI |
|---|---|---|
| Price | $88.76 | $15.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $130.86 | $21.55 |
| AVG Volume (30 Days) | 239.8K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ 35.18 | 31.91 |
| EPS | ★ 5.29 | N/A |
| Revenue | ★ $4,122,017,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $16.44 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $84.33 | $8.24 |
| 52 Week High | $159.66 | $20.22 |
| Indicator | LCII | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.11 |
| Support Level | N/A | $13.08 |
| Resistance Level | N/A | $15.96 |
| Average True Range (ATR) | 0.00 | 0.61 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 0.00 | 15.78 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries, including buses and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments: the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.